Detalles de la búsqueda
1.
Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer.
J Natl Compr Canc Netw
; 16(12): 1481-1488, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30545995
2.
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Lancet Oncol
; 17(6): 747-756, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27160475
3.
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Lancet Oncol
; 16(7): 787-94, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26028518
4.
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Lancet Oncol
; 15(13): 1442-1450, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25456363
5.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(2): 149-58, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23306100
6.
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clin Genitourin Cancer
; 19(4): e216-e222, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33753043
7.
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Eur Urol
; 73(6): 847-855, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29475737
8.
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Eur Urol
; 73(5): 696-703, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29074061
9.
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
Int J Radiat Oncol Biol Phys
; 94(1): 85-92, 2016 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26576711
10.
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Eur Urol
; 70(2): 256-62, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26610858
11.
Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU).
Cancer Treat Rev
; 41(10): 814-20, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26508669
12.
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Eur Urol
; 68(2): 196-204, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25277272
13.
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Eur J Cancer
; 50(5): 953-62, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24424105
Resultados
1 -
13
de 13
1
Próxima >
>>